Controlling Aedes mosquitoes in Kinshasa
Implementation and Evaluation of Vector Control Methods in Kinshasa: The Case of Aedes, Vectors of Arboviruses.
This study is testing different ways to control Aedes mosquitoes in Kinshasa to see if it helps reduce the spread of diseases like dengue and chikungunya.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 2050 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Institute of Tropical Medicine, Belgium Academic / other |
| Locations | 1 site (Kinshasa, République Démocratique Du Congo) |
| Trial ID | NCT06981442 on ClinicalTrials.gov |
What this trial studies
This study aims to implement and evaluate various strategies for controlling Aedes mosquitoes, which are responsible for transmitting diseases like dengue and chikungunya, in Kinshasa, Democratic Republic of the Congo. It will utilize a before-and-after interventional approach to assess the effectiveness of community-based environmental management and targeted vector control methods at different life stages of the mosquitoes. Additionally, a serological survey will be conducted to gather data on the prevalence of Aedes-borne diseases in the area, enhancing understanding of their circulation.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older who reside in selected health areas of Kinshasa and consent to participate.
Not a fit: Patients who are under 18 years of age, seriously ill, or not residing in the designated health zones may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could significantly reduce the incidence of Aedes-borne diseases in the affected populations.
How similar studies have performed: Other studies have shown success with similar vector control approaches, indicating potential for effective interventions in this context.
Eligibility criteria
Show full inclusion / exclusion criteria
At household level: Inclusion Criteria: * Belong to a household in one of the 4 health areas selected as study arms * From 18 years of age to consent for household enrollment and participation in the serosurvey * Consenting Exclusion Criteria: * Not belong to a household in one of the 4 health areas selected as study arms * Under 18 years of age * Non-consenting At health facility level: Inclusion Criteria: * From 18 years of age * Resident of the health zone of Mont Ngafula 1 * Consenting Exclusion Criteria: * Under 18 years of age * Not resident in the health zone of Mont Ngafula 1 * Seriously ill and hospitalized, requiring transfusion, presence of blood clotting disorders, allergies resulting from injections, adverse events associated with previous blood sampling, pregnancy * Non-consenting
Where this trial is running
Kinshasa, République Démocratique Du Congo
- Institut National de Recherche Biomédicale, INRB — Kinshasa, République Démocratique Du Congo, Democratic Republic of the Congo (Recruiting)
Study contacts
- Principal investigator: Veerle Vanlerberghe — Institute of Tropical Medicine Antwerp
- Study coordinator: Luciana Lepore
- Email: llepore@itg.be
- Phone: +32(0)32476666
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.